HealthEquity (NASDAQ:HQY) Updates FY25 Earnings Guidance

HealthEquity (NASDAQ:HQY) updated its FY25 earnings guidance on Monday. The company provided EPS guidance of 3.08-3.16 for the period, compared to the consensus EPS estimate of $3.12. The company issued revenue guidance of $1.185-1.195 billion, compared to the consensus revenue estimate of $1.18 billion.

Analysts Set New Price Targets

Several brokerages have issued reports on HQY. Royal Bank of Canada reiterated an “outperform” rating and set a $92.00 target price on shares of HealthEquity in a report on Wednesday, September 4th. Bank of America boosted their price target on HealthEquity from $100.00 to $120.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Mizuho started coverage on HealthEquity in a research report on Wednesday, December 4th. They set an “outperform” rating and a $126.00 price objective on the stock. BTIG Research boosted their target price on shares of HealthEquity from $110.00 to $130.00 and gave the stock a “buy” rating in a report on Thursday, November 14th. Finally, JMP Securities reiterated a “market outperform” rating and set a $105.00 price objective on shares of HealthEquity in a research note on Wednesday, September 4th. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $109.64.

HealthEquity Stock Performance

HQY traded up $0.79 during trading on Monday, reaching $101.00. 1,220,609 shares of the company’s stock were exchanged, compared to its average volume of 626,324. The company has a debt-to-equity ratio of 0.51, a current ratio of 4.10 and a quick ratio of 4.10. HealthEquity has a 1 year low of $62.10 and a 1 year high of $105.82. The company’s fifty day simple moving average is $92.42 and its 200-day simple moving average is $83.64. The stock has a market capitalization of $8.82 billion, a P/E ratio of 84.53, a price-to-earnings-growth ratio of 1.57 and a beta of 0.55.

Insider Buying and Selling

In other news, Director Robert W. Selander sold 8,250 shares of HealthEquity stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $82.98, for a total transaction of $684,585.00. Following the completion of the transaction, the director now directly owns 54,719 shares of the company’s stock, valued at $4,540,582.62. The trade was a 13.10 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Frank Corvino sold 1,247 shares of the stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $80.26, for a total transaction of $100,084.22. Following the sale, the director now directly owns 4,823 shares in the company, valued at $387,093.98. This trade represents a 20.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 10,536 shares of company stock valued at $884,517 over the last 90 days. Insiders own 2.20% of the company’s stock.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.